Zacks Investment Research
10 Sept 2026, 18:50 UTC · 13h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Bristol Myers Squibb's subcutaneous drug Opdivo Qvantig has surpassed $1 billion in annualized revenues. — Rapid scaling of a billion-dollar product helps offset revenue losses from legacy versions of blockbuster drugs.
+0.50The company's 'Growth Portfolio' contributed approximately 56% of total revenues in the first half of 2026. — Demonstrates a successful transition toward newer products to sustain top-line growth.
+0.30Bristol Myers Squibb shares have gained 19.4% year-to-date, significantly outperforming the industry's 6.3% growth. — Confirms strong existing momentum and investor confidence, though it is a lagging indicator.
+0.10Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
3h ago
